Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Atkins

Showing results (11-20 of 338) with videos related to

Pageof 34
Sort By:
Expert Opinion on Biological Therapy|January 27, 2025
How should we approach salvage therapy in advanced renal cell carcinoma after first-line immunotherapy combinations?Paul Sackstein, Michael B Atkins
Cancer Treatment and Research|November 26, 2015
Treatment of Melanoma CNS MetastasesSekwon Jang, Michael B Atkins
Journal of the National Cancer Institute|February 4, 2016
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current PerspectivesMichael B Atkins, James Larkin
Expert Review of Anticancer Therapy|April 28, 2022
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumabMichael Serzan, Michael B Atkins
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Systemic therapy for renal cell carcinomaYoo-Joung Ko, Michael B Atkins
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2015
Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic MelanomaGeoffrey T Gibney, Michael B Atkins
Cancer Journal (Sudbury, Mass.)|October 7, 2008
Immunotherapy of metastatic renal cell carcinomaDavid F McDermott, Michael B Atkins
Expert Review of Anticancer Therapy|December 26, 2006
Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistanceHenry B Koon, Michael B Atkins
Hematology/Oncology Clinics of North America|July 19, 2011
Future directions in renal cell carcinoma: 2011 and beyondDaniel C Cho, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Rupal S Bhatt, Michael B Atkins
Pageof 34

Showing results (11-20 of 338) with videos related to

Sort By:
Pageof 34
Expert Opinion on Biological Therapy|January 27, 2025
How should we approach salvage therapy in advanced renal cell carcinoma after first-line immunotherapy combinations?Paul Sackstein, Michael B Atkins
Cancer Treatment and Research|November 26, 2015
Treatment of Melanoma CNS MetastasesSekwon Jang, Michael B Atkins
Journal of the National Cancer Institute|February 4, 2016
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current PerspectivesMichael B Atkins, James Larkin
Expert Review of Anticancer Therapy|April 28, 2022
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumabMichael Serzan, Michael B Atkins
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Systemic therapy for renal cell carcinomaYoo-Joung Ko, Michael B Atkins
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2015
Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic MelanomaGeoffrey T Gibney, Michael B Atkins
Cancer Journal (Sudbury, Mass.)|October 7, 2008
Immunotherapy of metastatic renal cell carcinomaDavid F McDermott, Michael B Atkins
Expert Review of Anticancer Therapy|December 26, 2006
Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistanceHenry B Koon, Michael B Atkins
Hematology/Oncology Clinics of North America|July 19, 2011
Future directions in renal cell carcinoma: 2011 and beyondDaniel C Cho, Michael B Atkins
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Rupal S Bhatt, Michael B Atkins
Pageof 34